US Drug Recall Register

FDA Drug Recalls

14,450 recalls · Class II, newest first

Class II · Moderate risk Ongoing

Rocuronium Bromide 50 mg per 5mL

Reason Lack of Assurance of Sterility: Leaking/damaged syringes.

Denver Solutions, LLC DBA Leiters Health D-0374-2025
Class II · Moderate risk Ongoing

Ketamine HCl 50mg per 5mL

Reason Lack of Assurance of Sterility: Leaking/damaged syringes.

Denver Solutions, LLC DBA Leiters Health D-0373-2025
Class II · Moderate risk Ongoing

PHENYLephrine HCl in 0.9% Sodium Chloride

Reason Lack of Assurance of Sterility: Leaking/damaged syringes.

Denver Solutions, LLC DBA Leiters Health D-0372-2025
Class II · Moderate risk Ongoing

dexmedeTOMIDine HCl PF

Reason Lack of Assurance of Sterility: Leaking/damaged syringes.

Denver Solutions, LLC DBA Leiters Health D-0371-2025
Class II · Moderate risk Ongoing

Glycopyrrolate

Reason Lack of Assurance of Sterility: Leaking/damaged syringes.

Denver Solutions, LLC DBA Leiters Health NDC 71449-104-11 D-0370-2025
Class II · Moderate risk Ongoing

Unisom

Reason CGMP Deviations; detection of Nitrosamine Drug Substance-Related Impurities (NDSRI), N-nitroso-desmethyl-diphenhydramine (n-dph), above the FDA Recommended Intake Limit

Chattem Inc D-0362-2025
Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules

Reason CGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.

Breckenridge Pharmaceutical, Inc. NDC 51991-747-10 D-0308-2025
Class II · Moderate risk Ongoing

Clindamycin HCl

Reason CGMP Deviations

RemedyRepack Inc. D-0378-2025
Class II · Moderate risk Terminated

Voriconazole Tablets

Reason cGMP Deviations: Received notification from their supplier requesting they perform a recall due to the fact they repackaged the product.

Amerisource Health Services LLC NDC 60687-294-21 D-0307-2025
Class II · Moderate risk Ongoing

Haloperidol Decanoate Injection

Reason Lack of Assurance of Sterility: Media fill with bacterial contamination

Somerset Therapeutics Private Limited NDC 70069-383-10 D-0358-2025
Class II · Moderate risk Ongoing

Haloperidol Decanoate Injection 100mg/mL

Reason Lack of Assurance of Sterility: Media fill with bacterial contamination

Somerset Therapeutics Private Limited NDC 68001-581-41 D-0357-2025
Class II · Moderate risk Ongoing

Haloperidol Decanoate Injection 50mg/mL

Reason Lack of Assurance of Sterility: Media fill with bacterial contamination

Somerset Therapeutics Private Limited NDC 68001-580-41 D-0356-2025
Class II · Moderate risk Ongoing

Haloperidol Decanoate Injection 50mg/mL

Reason Lack of Assurance of Sterility: Media fill with bacterial contamination

Somerset Therapeutics Private Limited NDC 70069-381-01 D-0355-2025
Class II · Moderate risk Ongoing

Methocarbamol Injection USP 1

Reason Lack of Assurance of Sterility: Media fill with bacterial contamination

Somerset Therapeutics Private Limited NDC 70069-101-25 D-0354-2025
Class II · Moderate risk Completed

Venlafaxine Tablets

Reason Presence of Foreign Substance: Product complaint received for the presence of foreign material embedded resembling a metal shaving in one tablet.

Zydus Pharmaceuticals (USA) Inc NDC 68382-021-01 D-0310-2025
Class II · Moderate risk Ongoing

Atorvastatin Calcium Tablets USP 40 mg

Reason Failed dissolution specifications: lower than specifications

Biocon Pharma INC NDC 70377-079-13 D-0306-2025
Class II · Moderate risk Ongoing

Pravastatin Sodium Tablets

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 16714-570-02 D-0350-2025
Class II · Moderate risk Ongoing

Pravastatin Sodium Tablets

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 16714-559-01 D-0349-2025
Class II · Moderate risk Ongoing

Cetirizine Hydrochloride Tablets

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 72657-129-35 D-0348-2025
Class II · Moderate risk Ongoing

Acetaminophen and Ibuprofen

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 72657-157-74 D-0347-2025
Class II · Moderate risk Ongoing

Naproxen Sodium Tablets

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 68462-179-01 D-0346-2025
Class II · Moderate risk Ongoing

Saxagliptin Tablets

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 68462-726-30 D-0345-2025